An old epilep­sy med gets oral liq­uid for­mu­la­tion nod; PMV pairs up AS­CO stand­out with Keytru­da

The FDA ap­proved an oral liq­uid for­mu­la­tion of the drug zon­isamide, orig­i­nal­ly made by Eton Phar­ma­ceu­ti­cals and cur­rent­ly owned by Azu­ri­ty Phar­ma­ceu­ti­cals.

The nod gives Azu­ri­ty the abil­i­ty to mar­ket Zon­isade as an ad­junc­tive ther­a­py for treat­ing par­tial seizures in adults and kids 16 years and old­er who have epilep­sy. The green light comes af­ter three dou­ble-blind and place­bo-con­trolled clin­i­cal stud­ies of the drug, which is ad­min­is­tered once or twice a day. Zon­isamide was orig­i­nal­ly ap­proved in the ear­ly 2000s as a cap­sule for treat­ing par­tial epilep­tic seizures and has been mar­ket­ed by a va­ri­ety of com­pa­nies, in­clud­ing the for­mer Irish biotech Elan Phar­ma­ceu­ti­cals, Japan­ese drug­mak­er Ei­sai and Sum­it­o­mo Dainip­pon. In 2010, Elan and Ei­sai agreed to pay $214.5 mil­lion to re­solve al­le­ga­tions of off-la­bel mar­ket­ing of Zone­gran.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.